EntryPoint Capital LLC Invests $528,000 in OrthoPediatrics Corp. (NASDAQ:KIDS)

EntryPoint Capital LLC acquired a new position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 22,793 shares of the company’s stock, valued at approximately $528,000. EntryPoint Capital LLC owned about 0.09% of OrthoPediatrics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in shares of OrthoPediatrics during the 4th quarter worth approximately $79,000. American Century Companies Inc. raised its position in OrthoPediatrics by 13.2% during the fourth quarter. American Century Companies Inc. now owns 26,410 shares of the company’s stock worth $612,000 after acquiring an additional 3,072 shares in the last quarter. HighTower Advisors LLC bought a new stake in OrthoPediatrics during the fourth quarter worth $268,000. Charles Schwab Investment Management Inc. lifted its stake in OrthoPediatrics by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 136,234 shares of the company’s stock valued at $3,158,000 after acquiring an additional 3,800 shares during the last quarter. Finally, Mutual of America Capital Management LLC grew its position in shares of OrthoPediatrics by 57.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 169,021 shares of the company’s stock valued at $3,918,000 after acquiring an additional 61,412 shares during the period. Institutional investors and hedge funds own 69.05% of the company’s stock.

Insiders Place Their Bets

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 5,310 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the transaction, the general counsel now owns 110,767 shares in the company, valued at $2,753,667.62. This trade represents a 4.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David R. Bailey sold 6,620 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the sale, the chief executive officer now owns 319,155 shares of the company’s stock, valued at approximately $7,934,193.30. The trade was a 2.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,732 shares of company stock worth $589,978 in the last quarter. 31.80% of the stock is currently owned by corporate insiders.

OrthoPediatrics Price Performance

OrthoPediatrics stock opened at $24.86 on Tuesday. The company has a market capitalization of $603.77 million, a price-to-earnings ratio of -20.21 and a beta of 1.22. The stock’s 50 day moving average is $24.84 and its 200-day moving average is $25.37. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. OrthoPediatrics Corp. has a 12 month low of $21.02 and a 12 month high of $35.99.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. The firm had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same quarter last year, the business earned ($0.23) EPS. Equities research analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on KIDS shares. Stifel Nicolaus cut their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, March 5th. Needham & Company LLC reissued a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, March 5th. Finally, Truist Financial cut their price target on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a report on Wednesday, December 18th.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.